Eggshell Weekly Report 0528: 27 Financing Deals This Week, State Council Encourages Multi-tiered and Diversified Medical Services
VCBeat Headlines
Real-World Feedback on Medical AI: How Do Seven Types of Physicians View Its Value? | ||
Since gaining prominence in the second half of 2016, medical artificial intelligence (AI) has seen over a year of intensive development. Many companies’ AI products are now undergoing clinical trials, while others have already been commercialized and are being sold as they explore revenue models. What is the actual impact of AI products on physicians after they begin using them? Furthermore, what are the attitudes of physicians at different career stages toward AI after its adoption? | ||
Artificial Intelligence | 2017-05-22 | |
As the most exploratory application under the grand trend of “Internet + Healthcare,” internet hospitals span multiple disciplines, including medicine, management, and internet technology. Who are the leaders steering these internet hospitals? What are their distinguishing characteristics? How do they manage internet hospitals, and how effective is their management? | ||
Internet Hospital | 2017-05-23 | |
Analysis of the Trend in Prescription Outflow: Market Size May Reach RMB 800 Billion by 2020 | ||
The previously existing issues in prescription outflow, such as misalignment with medical insurance systems, difficulties in settlement, and the inability of retail pharmacies to absorb the outflowing prescriptions, have garnered significant attention. Consequently, the external circulation of prescriptions will become a key focus of this year’s healthcare reform initiatives. In light of this, VCBeat has drafted a preliminary report on prescription outflow trends, offering a brief discussion on the issue of external prescription circulation. | ||
Medicine | 2017-05-24 | |
Since Bristol Myers Squibb launched the first PD-1 drug, Opdivo, in the United States, major pharmaceutical companies have flocked to join the immunotherapy race. Merck’s Keytruda and Roche’s PD-L1 inhibitor Tecentriq have successively received FDA approval, while China’s pharmaceutical industry holds high expectations for PD-1/PD-L1 therapies. | ||
Biotechnology | 2017-05-25 | |
This conference was hosted by the China Association for the Promotion of Rehabilitation Technology Transformation and Development, co-hosted by VCBeat and VBInsight, and co-organized by the Sichuan Provincial Investment Promotion Bureau, the Sichuan Health Information Society, and the Hierarchical Diagnosis and Treatment System Engineering Professional Committee of the China Association for the Promotion of Rehabilitation Technology Transformation and Development. Regarding how to empower primary healthcare, VCBeat shares with you some insights from the attending guests for our readers’ benefit. | ||
Primary Healthcare | 2017-05-26 | |
Artery View
New Investment Opportunities in Primary Healthcare: Most Bullish on Two Types of Companies
Executive Director, Legend CapitalWang Jianfei
Regarding healthcare investment, Wang Jianfei first shared the core investment logic for the entire medical and health services sector. In summary, it is essential to grasp the primary contradictions within the industry and identify investment opportunities by focusing on solving key problems.
Wang Jianfei believes that the main issues China’s healthcare system needs to address are: diversified payment methods, improving the efficiency of public medical service systems, and meeting the demands of consumption upgrades. Among these, the most core and prominent driving force behind the new healthcare reform is the payment segment, which constitutes the first key point.
AI Empowers Primary-Care Radiologists to Deliver Tertiary Hospital-Level Diagnoses
Founder of Infervision Chen Kuan
Traditional artificial intelligence algorithms require extensive manual guidance from experts to instruct computers on how to perform recognition. Taking pulmonary tuberculosis as an example, deep learning only requires the provision of large volumes of data, with annotations indicating which cases are pulmonary tuberculosis, which represent normal vascular interruptions, and which are normal. The deep learning algorithm gradually establishes diagnostic criteria based on this data, thereby automating the diagnostic process.
Overall, deep learning does not require manual feature extraction; it only needs a large amount of valid data, allowing the algorithm to learn recognition autonomously. Traditional algorithms rely on feature extraction for identification. However, medical scenarios are highly complex, and features cannot fully encompass all possible cases. For instance, if a woman disguises herself as a nun, traditional artificial intelligence would struggle to determine her gender, whereas deep learning can identify her as a female, much like human judgment.
KPMG China Director, Healthcare Industry Alexander Brookes
Addressing these challenges requires not only cooperation between physicians and patients but also support from the media. The media must communicate to the public the roles and advantages of the new healthcare system, fostering understanding before acceptance. Furthermore, a systematically managed team is needed to lead such reforms, ensuring the system’s sustained and effective operation.
It is crucial to recognize that the integration of healthcare systems should not be pursued with a short-sighted focus on immediate gains. Relevant data indicate that countries attempting to achieve this within a short timeframe have failed. In contrast, more successful nations have typically started from the ground up, persisted with incremental changes, emphasized employee incentive mechanisms, and maintained staff initiative. Throughout this process, they have ensured timely feedback, discussion, and continuous improvement.
Capital Dynamics
This week, there are a total of27Financing Event.
Domestic | |||
Project | Business | Funding Amount | Major Investors |
Fuei Medical Aesthetics | Skin Aesthetics Management Institution | Not disclosed | Legend Capital,Ares Management,Shiyu Capital, Zhengqi Finance |
EDiagnosis | Medical Imaging Diagnostic Platform | Tens of millions of RMB | Xi'an Jiaotong University Sci-Tech Innovation Fund |
Jingquan Chinese Medicine | Production and Sales of Traditional Chinese Medicine Decoction Pieces | RMB 110 million | For Realcan Pharmaceutical Co., Ltd. |
Zhongke Chuangxiang | Telemedicine Online Diagnosis Platform | RMB 10 million | Individual Investor Zhang Chunlong |
Canhelp Genomics | Medical Technology Enterprise | $25 million | Chongde Yingsheng, Zhongling Yan Yuan, Longpan Fund, Qiming Venture Partners, WuXi AppTec, Yuanming Capital |
Jiahe Meikang | Developer of Medical Information Management Software | RMB 330 million | Alibaba Health (Alibaba) |
Abroad | |||
Project | Business | Financing Amount | Major Investors |
Harpoon Therapeutics | Immuno-Oncology Company | 45 million | Taiho Ventures,New Leaf Venture Partners |
EarLens | Hearing Aid Developer | 21 million | Lightstone Ventures,New Enterprise Associates |
Vapotherm | Developer of Advanced Respiratory Care Technologies | 20 million | Gilde Healthcare Partners |
Viz.ai | AI Ultrasound Recognition | 7.5 million | AME Cloud Ventures |
Scopio Labs | Medical Imaging Diagnostic Platform | 7 million | OurCrowd |
DocPlanner | Online Medical Appointment Platform | 16.7 million | One Peak Partners |
Bayzat | Health Insurance Selection Support Platform | 3 million | - |
TP Therapeutics | Anticancer Drug Development Company | 45 million | Eli Lilly Asia Venture Capital,S. R. One |
Anaconda Biomed | Medical Device Company | 16.9 million | Ysios Capital Partners |
Castor EDC | Medical Electronic Data Capture Services | 1.23 million | Horizon 2020 |
VitalConnect | Health Monitoring and Intervention | 33 million | MVM Life Science Partners |
Ivbar | Healthcare Data Analytics | 5.74 million | Summa Equity |
Policy Updates
Policy Documents
Regulation Name | Date of Publication | Issuing Authority | Document Number |
Implementation Opinions on Further Strengthening the Construction of Professional Ethics and Rectifying Kickbacks in the Pharmaceutical Industry | 2017-05-26 | Shanghai Municipal Health and Family Planning Commission | Shanghai Health and Family Planning Discipline Inspection[2017]003No. |
Announcement of the Guangzhou Municipal Human Resources and Social Security Bureau on Publicly Soliciting Comments on the "Guangzhou Long-Term Care Insurance Trial Measures (Draft for Comment)" | 2017-05-22 | Guangzhou Municipal Human Resources and Social Security Bureau, Guangdong Province | Guangzhou Human Resources and Social Security Bureau Notice[2017]6No. |
Announcement of the China Food and Drug Administration on the Handling of Issues Related to the Verification of Clinical Trial Data for Drugs | 2017-05-22 | China Food and Drug Administration | Announcement of the China Food and Drug Administration2017Year63No. |
Notice of the General Office of the Ministry of Industry and Information Technology, the General Office of the National Health and Family Planning Commission, the General Office of the National Development and Reform Commission, and the General Office of the China Food and Drug Administration on the Continuation of the Pilot Program for the Designated Production of Certain Varieties in the First Batch of Essential Medicines | 2017-05-19 | Ministry of Industry and Information Technology; National Development and Reform Commission; National Health and Family Planning Commission; China Food and Drug Administration | MIIT Joint Consumption[2017]52No. |
Notice on Issuing the "Implementation Plan for Government Affairs Transparency Work of the Shanghai Municipal Health and Family Planning Commission in 2017" | 2017-05-19 | Office of the Shanghai Municipal Health and Family Planning Commission | Shanghai Health and Family Planning Commission Office[2017]2No. |
Opinions of the General Office of the State Council on Supporting Social Forces in Providing Multi-level and Diversified Medical Services | 2017-05-16 | General Office of the State Council | No. [Year] of the General Office of the State Council[2017]44No. |
Key Policy Highlights
From the perspective of the supply side of medical services, government-run healthcare institutions are primarily responsible for ensuring the most core and basic medical and health services, thereby guaranteeing universal access to these public goods. However, relying solely on government efforts is insufficient to meet the people’s increasingly diverse health needs. It is essential to more comprehensively and fully leverage resources across society, increase the supply of multi-tiered and diversified medical services, and complement government-provided care. This approach not only alleviates patients’ concerns about seeking treatment and fulfills their expectations for improved physical and mental well-being, but also expands investment in the healthcare sector, stimulates health-related consumption, creates related employment opportunities, and fosters new drivers of economic growth, yielding multiple benefits. | ||
Socially Operated Medical Institutions | ||
Event Preview
Name | Location | Time | Costs |
2017 Global Pharmaceutical Commercial Innovation Conference | Shanghai | 2017-06-06 2017-06-07 | 2800 |
2017 China International Medical Innovation Forum | Suzhou | 2017-06-10 | Free |
2017 DXY Digital Healthcare China | Suzhou | 2017-06-15 | Free |
2017 Artificial Intelligence and Data Application Forum | Guangzhou | 2017-06-16 2017-06-17 | 500 |
2017 Future Healthcare Technology Conference & Frontier Summit on Artificial Intelligence | Shanghai | 2017-06-15 2017-06-16 | 1000 |
2017 China Medical Affairs Summit | Shanghai | 2017-06-21 2017-06-23 | From 2,500 |
2017 The 4th China IVD Industry Investment and M&A CEO Forum | Hangzhou | 2017-06-28 2017-06-29 | Starting from 2,200 |
2017 China-US Summit on Intelligent Healthcare Big Data | Beijing | 2017-06-24 | 616 cases |
628 China Private Healthcare Internet Conference | Putian | 2017-06-28 | Free |
Industry Dynamics
Hot Topics
Alipay Partners with Hundsun Yuntai to Connect 1,500 Hospitals and 15 Healthcare Startups via Its Medical Service Platform | |||||
5Month9Recently, Alipay, under Ant Financial, partnered with Hangzhou Hengsheng Yuntai Network Technology Co., Ltd. to announce the launch of a one-stop “Medical Services” platform for individual users. In addition to integrating existing services on Alipay such as appointment registration and medical consultations, the platform enables users to access health consultations, health information, maternal and child care services, and health-related financial products.15Health management services. | |||||
Medical Insurance Payment | |||||
Merck’s PD-1 Drug Keytruda Achieves Overwhelming Victory in Lung Cancer Field! | |||||
On May 10, Merck announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Keytruda (pembrolizumab) in combination with chemotherapy (pemetrexed plus carboplatin) as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). Previously, Keytruda was the only PD-1/PD-L1 inhibitor approved for first-line treatment of NSCLC; this new approval further expands its indications. From a market perspective, Keytruda has established an overwhelming advantage in the lung cancer field, far surpassing other PD-1/PD-L1 inhibitors rather than merely maintaining a slight lead. | |||||
Pharmaceuticals | |||||
CFDA Completely Abolishes Qualification Accreditation for Clinical Trial Institutions and Accepts Overseas Data | |||||
On May 11, the China Food and Drug Administration (CFDA) issued a late-night announcement to further deepen the reform of the review and approval system, promote structural adjustment and technological innovation in the pharmaceutical and medical device industries, completely abolish the qualification accreditation for clinical trial institutions, and replace it with a record-filing management system. Meanwhile, social capital is encouraged to invest in establishing clinical trial institutions to provide professional clinical trial services. Furthermore, overseas enterprises and research institutions are permitted to conduct Phase I clinical drug trials in China. | |||||
CFDA | |||||
DomesticPET/CTBreaking the monopoly of foreign enterprises, with “GPS”Striving for Dominance | |||||
The successful maiden flight of China’s domestically produced C919 aircraft and the nationwide rollout of high-speed rail have once again ignited national pride, as these flagship achievements significantly impact our daily lives. Similarly, a landmark innovation has emerged in the healthcare sector: the launch of Rayseecon’s PET/CT system. This development not only breaks the monopoly long held by the “GPS” giants (GE, Philips, and Siemens) but also drives down the price of PET/CT equipment substantially. In light of this, VCBeat conducted an exclusive interview with Liu Yajing, Vice President of Beijing Rayseecon Technology Development Co., Ltd. | |||||
Medical Devices | |||||
Pfizer andSangamoSignature$5.45Billion-Yuan Agreement to Bolster Hemophilia Treatment | |||||
Pfizer, the U.S. pharmaceutical giant (Pfizer) recently announced a partnership with the gene therapy companySangamo TherapeuticsReached an exclusive global collaboration and licensing agreement to develop and commercialize multiple gene therapy programs forATreatment of hematologic malignancies, includingSB-525, this isSangamoCompany4one of the lead candidate drugs, expected to enter human clinical development this quarter. | |||||
Pharmaceuticals | |||||
Listed Company
Alibaba Health | Investment | ||
5Month22VCBeat reported that Alibaba Health recently announced that its subsidiary, Hongyun Jiukang, intends to invest in the healthcare information software provider Jiahemed (Beijing) Technology Co., Ltd. and its subsidiary, Beijing Jiamei Online. Alibaba Health stated that this year5Month19On [date], Hongyun Jiukang (a subsidiary of the Company) entered into a capital increase agreement with Jiahe Meikang, pursuant to which Hongyun Jiukang will inject cash into the latter.2.91100 million yuan, will hold its15%rights and interests. On the same day, Hongyun Jiukang also increased its capital investment in Beijing Jiamei Online Technology Co., Ltd.400010,000 yuan in cash, will hold its45%Rights and interests. | |||
BGI Genomics | Listing | ||
5Month24On the afternoon of [date], BGI Genomics officially passed the review! According to BGI Genomics' prospectus, the company plans to issue400010,000 shares, fundraising17.32hundred million yuan, with its estimated issue price at43.3around RMB. Based on the current pace from committee review to issuance of approval documents(15around days)and the ChiNext weekly4Jiafa | |||
Medical Consultation160 | Investment | ||
5Month24Day, Medical Visit160(Ningyuan Technology) issued an announcement, stating that its subsidiary Shenzhen Renren Health intends to1acquire Shenzhen Wuchuang Health Consulting Management Co., Ltd. at a price of RMB20%equity interest. | |||
Fangsheng Pharmaceutical | Investment | ||
5Month23VCBeat News: Fangsheng Pharmaceutical, a listed pharmaceutical company, announced that it has decided to jointly establish the Tongxi Fangsheng Medical Industry Investment Fund (tentative name, subject to approval by the industrial and commercial registration authorities) with Tongxi Capital. | |||
Renhe Pharmaceutical | Cooperation | ||
5Month26News Flash: Recently, Renhe Pharmacy Network and Datebao publicly announced the establishment of a strategic partnership. The two parties will collaborate on health big data, integrate their respective channel resources, and further enhance public awareness of health insurance. | |||
WuXi AppTec | Listing | ||
5Month24On [date], Reuters cited sales documents revealing that WuXi Biologics, a mainland China-based biologics contract development and manufacturing organization (CDMO), plans to list on the Main Board, offering approximately1.93billion shares, equivalent to the expanded share capital17%, where88%for new shares,12%as existing shares, and within the total number of shares offered in this IPO,90%International Placement,10%For public offering. | |||
Frontiers of Technology
PiwiGene Mutation | Application Areas | Assisted Reproductive Technology |
In a collaborative study, the research group led by Liu Mofang at the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, and the research group led by Shi Huijuan at the Shanghai Institute of Planned Parenthood Research have discovered for the first time that mutations in human Piwi genes can cause male infertility. Their work further elucidates the underlying pathogenic mechanisms, providing a theoretical basis for early molecular diagnosis and precision medicine for related forms of male infertility. | ||
Graphene Sensors | Application Areas | Respiration |
Recently, scientists at Rutgers University in the United States have developed a graphene-based sensor capable of early detection and warning of asthma attacks, thereby improving the treatment of respiratory diseases such as asthma. | ||
Pediatric Esophageal Atresia Devices | Application Areas | Pediatrics |
On May 12, 2017, the U.S. Food and Drug Administration (FDA) approved a pediatric esophageal atresia anastomotic device developed by Wilson-Cook Medical Inc., marking the first FDA-approved medical device for esophageal atresia (EA) in infants under one year of age. | ||
Immunotherapy DrugsPD1InhibitorKeytruda | Application Areas | Tumor |
The U.S. FDA has granted accelerated approval to Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR). Previously, the FDA had consistently based its approvals on the cancer’s location in the body | ||
DigitalizationXRadiographic Fluoroscopy System | Application Areas | Tumor |
This product enables patients to remain completely motionless. By leveraging true 3D imaging technology, it facilitates whole-body imaging in both standing and supine positions. It is particularly effective for weight-bearing standing examinations of the knee, ankle, hip, and spine, thereby overcoming the limitations of conventional CT systems.approval of anticancer therapies based on the tumor’s site of origin, such as lung cancer and breast cancer. This time, a drug was approved based on tumor biomarkers, regardless of the tumor’s site of origin! | ||
Intelligent Examination System for Lymphocyte Micronuclei | Application Areas | Clinical Diagnosis |
Recently, Yasen Technology, in partnership with the Central Laboratory of the Second Affiliated Hospital of Xiamen Medical College, announced the joint development of an intelligent inspection system for lymphocyte micronuclei. Leveraging novel artificial intelligence technologies, the system assesses lymphocyte micronucleus rates and achieves a fully automated workflow encompassing slide preparation, scanning, identification, and statistical analysis. Currently, the system’s automatic detection rate for micronucleated cells90%The above. | ||
Study Watch | Application Areas | Health Management |
Recently,VerilyNew developments have emerged, according toCBINSIGHTAccording to a patent search engine, one of their new patents has just been granted. This diagnostic system uses wearable devices to monitor and evaluate specific substances inserted into or ingested by the human body. By monitoring the types of particles interacting with these substances, the system can provide device users with feedback on potential disease risks. | ||
In-Depth Report
Report Name | Publisher | Content Introduction |
Medical Technology: The Next Big Opportunity for Emerging Market Companies | Boston Consulting Group | The report predicts that, driven by rising demand and global expansion, medical technology will emerge as one of the standout industries from emerging markets to reach the international stage, and outlines the respective competitive advantages of multinational corporations and local enterprises. |
2017 Global Life Sciences Industry Outlook: Seeking Growth in an Uncertain Market | Deloitte | The report presents an overview of the current state of the global life sciences industry, examines trends and issues affecting various market segments and organizations, and provides recommendations for shareholders seeking revenue growth and increased market share. |
Detailed weekly report content can be accessed in the VCBeat knowledge base!
Report Planning | VCBeat VCBeat Content Center |
Producer | Wang Guanglong |
touchlife1 |